AOD-9604
Category 1Also known as: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
MetabolicLast reviewed: April 28, 2026
A modified fragment of human growth hormone (amino acids 177-191) originally developed as an anti-obesity agent. Targets fat metabolism without the growth-promoting effects of full HGH.
Mechanism of Action
Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) by mimicking the fat-reducing action of natural growth hormone without affecting blood sugar or tissue growth.
Common Uses
- Fat loss
- Metabolic health
- Body composition improvement
- Cartilage repair (emerging research)
Known Risks
- Limited efficacy data in humans
- Injection site reactions
- Headaches
- Phase 2 trials showed modest results
Regulatory Status
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Previously reached Phase 2 clinical trials for obesity but was not pursued further by the original developer. Available through licensed 503A compounding pharmacies with a physician prescription.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
300–500 mcg
Frequency
Once daily, fasted (morning)
Cycle Length
12–16 weeks
Take on empty stomach — food blunts the lipolytic effect. Often stacked with CJC-1295/Ipamorelin for combined fat loss and GH optimization.
Related Compounds
Research References
Related Articles
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.